Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer

Journal of Clinical Oncology

Volumn 19, Issue 1, 2001, Pages 81-88

  Rick, O ^a   Bokemeyer, C ^a   Beyer, J ^a   Hartmann, J T ^a   Schwella, N ^a   Kingreen, D ^a   Neureither, S ^a   Metzner, B ^a   Casper, J ^a   Wandt, H ^a   Hartmann, F ^a   Schmoll, H J ^a   Derigs, G ^a   Gerl, A ^a   Berdel, W E ^a   Kanz, L ^a   Siegert, W ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; IFOSFAMIDE; PACLITAXEL; THIOTEPA;

ARTICLE; AUTOTRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG MEGADOSE; GERM CELL TUMOR; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE ORGAN FAILURE; NEUROTOXICITY; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SALVAGE THERAPY; SENSORIMOTOR NEUROPATHY; SKIN TOXICITY; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; TUMOR GROWTH;

EID: 0035148199     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.1.81     Document Type: Article

References (27)

1. Dose-intensive chemotherapy in refractory germ cell cancer: A phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation
2. Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue
3. Germ cell tumors: Dose-intensive therapy
4. Early salvage therapy for germ cell cancer using high dose chemotherapy with autologous bone marrow support
5. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: A phase I/II study
6. High-dose versus conventional-dose first-salvage treatment in nonseminoma: A matched-pair analysis
7. High-dose chemotherapy as salvage treatment in germ cell tumors: A multivariate analysis of prognostic factors
8. Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors
9. Paclitaxel (T) containing first-line salvage therapy selected by risk for patients (pts) with germ cell tumors (GCT)
10. Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients
11. Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer
12. Feasibility of multiple courses of high-dose cyclophosphamide, thiotepa, and carboplatin for breast cancer or germ cell cancer
13. Impact of preleukapheresis cell counts on collection results and correlation of progenitor-cell dose with engraftment after high-dose chemotherapy in patients with germ cell cancer
14. Non-parametric estimation from incomplete observations
15. High-dose (HD) VIP-chemotherapy (Ctx) plus peripheral stem cell (PBPC) support as first-line therapy for advanced germ cell cancer
16. High-dose chemotherapy in germ cell tumours: A large single centre experience
17. Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: Response and survival
18. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor
19. Nephrotoxicity after high-dose carboplatin, etoposide and ifosfamide in germ-cell tumors: Incidence and implications for hematologic recovery and clinical outcome
20. Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors
21. Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma
22. Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: A phase II trial
23. Cisplatin and ifosfamide with either vinblastine or etoposide as salvage therapy for refractory or relapsing germ cell tumor patients
24. Clinical toxicities encountered with paclitaxel (TAXOL)
25. Paclitaxel-induced neuropathy
26. Neurotoxicity and ototoxicity of cisplatin plus paclitaxel in comparison to cisplatin plus cyclophosphamide in patients with epithelial ovarian cancer
27. High-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma